ABclonal Completes $93 Million Round Led by China Investors

ABclonal Biotechnology, a Massachusetts life science tools and services company, completed a $93 million Series C financing led by two China investors, Sequoia Capital China and LYFE Capital. ABclonal said it currently is negotiating to acquire a contract research organization focused on single-cell-based monoclonal antibody development. The acquisition would expand its R&D pipelines globally. ABclonal also plans to use the capital to expand the production capabilities of its research reagent products and services. More details.... Share this with colleagues: // //